You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Parameter Development for the Scaled Manufacturing of Mycelium Bound Panels for Commercial Interior Products

    SBC: Ecovative Design Llc            Topic: 16NCER6A

    Ecovative Design uses grown mycelium structures to bind agricultural and wood byproducts into inherently nontoxic_x000D_ products containing no added urea formaldehyde or flame-retardant chemicals. This research program focuses_x000D_ on maturing mycelium technology for use in the production of large scale board products, from low density (LD) particle board to acoustic panels and thermal insulati ...

    SBIR Phase II 2018 Environmental Protection Agency
  2. An Enhanced Contact Plasma Reactor: A Competitive Remediation Technology for Per- and Perfluoroalkyl Substance (PFAS) Contaminated Water

    SBC: DMAX PLASMA, INC.            Topic: 17NCER1A

    Perfluoroalkyl substances (PFASs) have received considerable attention due to their toxicity, ubiquitous presence and recalcitrance. Manufacture and disposal of PFAS-containing products has resulted in PFAS contamination of numerous water supplies. Recent reports indicate the Air Force alone is expecting to spend > $2.25 billion for cleanup for PFAS-contaminated sites. Thus, there is a huge market ...

    SBIR Phase I 2018 Environmental Protection Agency
  3. Green Process for Plastic Chrome

    SBC: VERGASON TECHNOLOGY INC            Topic: 17NCER5B

    This green approach to manufacturing plastic with decorative chrome will eliminate health and environmental hazards from the chrome electroplating process. The US and global market for decorative chrome on plastic is 12 million m2/year and 84 million m2/year respectively, with 80% in automobile trim, 10% in appliances and 10% in sanitary fixtures. Without a viable commercial alternative, US provid ...

    SBIR Phase I 2018 Environmental Protection Agency
  4. Synthetic Universal Flu Vaccine

    SBC: TRIA BIOSCIENCE CORP.            Topic: NCIRD

    Abstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is th ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  5. Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines

    SBC: HDT BIO CORP            Topic: NCIRD

    Project Summary SignificanceSinceavian influenza AH Nhas sickened overpeople with amortality rateHalf of all cases occurred inwhich also saw the emergence of a highly pathogenic strainThusH Navian influenza is poised to emerge as a devastating pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccineswhether attenuatedinactivatedsplit or recombinantare insufficiently imm ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting

    SBC: MedicaSafe Inc            Topic: NIDA

    PROJECT SUMMARY ABSTRACT Opioid use disorder is the leading cause of accidental death in the USwith overlethal drug overdoses inSAMHSA estimates thatmillion Americans misuse prescription opioids for non medical purposes annuallyPublic health officials and policymakers have acknowledged the urgent need for innovative approaches to the treatment of those with opioid use disorderin spite of thisthe a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Tau oligomer platform validation using lead series candidate in htau mice

    SBC: OLIGOMERIX INC            Topic: NIA

    TITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Gene and Stem Cell-Based Treatment for Tendinopathy

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: R

    Project SummaryTendinopathy is a common chronic tendon disorder that affectsof individuals overyears oldIt is characterized by painswellingloss of functionand impaired performanceThere is currently no cure for tendinopathySpontaneous repair or treatment typically leads to scar formationresulting in a weakened tissue with reduced function and mechanical properties that may ultimately rupture with f ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD

    SBC: OLIGOMERIX INC            Topic: NIA

    PROJECT SUMMARYSBIR RRFast Track ApplicationFOA NumberPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand AD related dementiasADRDwith tau pathologyThere is a critical unmet need for a disease modifying drugDMDfor ADChronic treatment strategies require safeeffectiveand economically feasible approaches such as small molecule drugsT ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government